Momenta Delays on Adalimumab In A Bid To Save On Costs
US filing previously slated for the current quarter is pushed back to an undisclosed date, with costs in mind; Momenta also plans to raise up to US$177.5 million through public offering.
You may also be interested in...
Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.
While 2018 was a record year for US biosimilar approvals and launches, companies are still struggling for market share in certain therapies and facing obstacles in getting their products over the line. Generics Bulletin rounds up where the leading players stand, ahead of financial results being published in the coming days and weeks.
Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.